Neurones S.A. (NRO.PA) • EURONEXT
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold NRO.PA in your mock portfolio yet.
With an EPS of €2.14 and a PE ratio of 18.27, Neurones S.A. appears reasonably valued relative to typical mature IT/services peers, suggesting neither obvious overvaluation nor deep value. The EPS level indicates solid underlying profitability, but without multi-period revenue and margin data, it is difficult to confirm a strong growth trajectory or margin expansion story. Overall, the financial snapshot points to a stable, profitable company rather than a high-growth or distressed profile.
The stock is trading at €39.10, essentially in line with its 200-day moving average of €39.26, suggesting the longer-term trend is flat to mildly positive. A 9.8% gain over the last month indicates recent positive momentum, but the proximity to the 200-day average implies the move is not yet a clear breakout. Without an explicit RSI reading, the technical picture looks balanced rather than strongly overbought or oversold.
Alternative data signals are mixed to negative, with the most concerning indicator being a 61.5% month-over-month drop in job openings, which can signal slowing expansion or heightened cost control. Web traffic is modest at about 5,627 visitors per month, and social media followings are small with flat to slightly declining trends on most platforms, suggesting limited brand reach or engagement momentum. LinkedIn remains the strongest channel with 22,016 followers, but overall digital and hiring signals lean cautious.
Overall, Neurones S.A. presents as a stable, reasonably valued, profitable company with modest recent share price momentum but no clear evidence of a strong growth inflection. The technical setup is balanced around the 200-day moving average, while alternative data—particularly the sharp decline in job postings—raises questions about the near-term growth outlook. Taken together, the signals support a neutral view on the stock at current levels.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started